Introduction
In 1999, the World Health Organization (WHO) estimated that 170 million individuals were chronically infected with the hepatitis C virus (HCV) worldwide. 1 Furthermore, it is now well established that hepatitis C develops into cirrhosis of the liver and hepatocellular carcinoma (HCC) both of which are fatal diseases. [2] [3] [4] [5] [6] These facts clearly indicate that HCV is an important public health problem globally.
To date, numerous data have been accumulated on the epidemiology of HCV infection. 7, 8 Accumulated data show that HCV genotypes vary in their distribution, which may have clinical significance. [9] [10] [11] The WHO estimates that there are at least 21.3 million HCV carriers in the Eastern Mediterranean countries, which is close to the number of carriers Summary It is well established that hepatitis C develops into cirrhosis of the liver and hepatocellular carcinoma (HCC) both of which are fatal diseases. The World Health Organization estimates that there are at least 21.3 million hepatitis C virus (HCV) carriers in the Eastern Mediterranean countries, which is close to the number of carriers estimated in the Americas and Europe combined. With such a high disease burden of HCV infection in this part of the world, and in light of the new evidence that genotypes may influence the outcome of antiviral therapy, the focus of this review is on the epidemiology and distribution of HCV genotypes in the Eastern Mediterranean countries. Accumulated data show that there are two main patterns for the distribution of HCV genotypes in the Middle East: in the first pattern, genotype 4 is prevalent in most of the Arab countries, and in the second pattern, genotype 1a or 1b predominates in the non-Arab countries. Results from the limited number of clinical trials on the treatment of chronic HCV genotype 4 using peginterferon alfa-2b in combination with ribavirin are encouraging. However, efforts to develop more effective antiviral therapies and the establishment of an effective HCV vaccine remain the largest challenges for the near future. # 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. estimated in the Americas (13.1 million) and Europe (8.9 million) combined. 1 Indeed, one of the highest prevalences of HCV infection (18.1%) has been reported from Egypt, a Middle Eastern country. 1 With such a high disease burden of HCV infection in this part of the world and in light of the new evidence that genotypes may influence the outcome of antiviral therapy, [12] [13] [14] [15] the focus of this review is on the epidemiology of HCV infection and distribution of HCV genotypes in the Eastern Mediterranean countries and possible implications for the future. However, since there have been dramatic advances in the diagnosis of HCV infection during the past decade, this article first reviews the molecular organization and the genetic diversity of the HCV genome, and then highlights the significance and reliability of the tests available for testing and confirmation of HCV genotypes.
HCV genome
Genomic organization HCV is an aspheric, enveloped virus classified in the Hepacivirus genus of the Flaviviridai family. 16 The viral genome is a single stranded linear RNA of positive sense. The genome is approximately 9.6 kb in size and contains an open reading frame (ORF) flanked by both a 5 0 and a 3 0 non-coding region (NC). 17 Immediately downstream of the 5 0 NC is the single ORF, which encodes a large protein polyprotein precursor. This precursor is subsequently cleaved by host and viral proteases into various structural and nonstructural proteins. The structural proteins are at the 5 0 end and include the capsid or core protein (c), two envelope proteins (E1 and E2) and a small protein of unknown function (P7). The structural proteins are followed by at least six nonstructural (NS) proteins denoted as NS2, NS3, NS4A, NS4B, NS5A, and NS5B. 10 
Genetic diversity of the HCV genome
Although both the 5 0 and 3 0 NC of the HCV genome possess highly conserved terminal sequences, 18 HCV is characterized by a high degree of genetic heterogeneity 19 and as such it is similar to other RNA viruses. The most heterogeneous regions of the genome are the genes encoding the two envelope proteins, E1 and E2. The N terminus of the E2 gene contains the most variable region of the entire genome and has been referred to as the first hypervariable region (HVR1). 20 A second hypervariable region, referred to as HVR2, is located just 3 0 of HVR1. 21 This genetic heterogeneity of HCV has been classified into four hierarchical strata: genotypes, subgenotypes (subtypes), isolates, and quasi-species. The degree of nucleotide sequence variation for each stratum (expressed as a percentage) is 30-50%, 15-30%, 5-15%, and 15%, respectively. 12, 22 A total of eleven major genotypes, designated according to the order of their discovery [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] have been identified 23, 24 and more than 90 subtypes have been described. An increasing number of novel subtypes is emerging and more detailed phylogenetic analysis of these isolates is recommended. 25, 26 Testing for HCV genotypes Many methods have been used for HCV genotyping including genomic amplification and sequencing, 27 restriction frag-ment length polymorphism (RFLP) of the PCR amplifications 28 and differential hybridization. 29 Among these direct methods, genomic amplification and sequencing, followed by sequence comparison and phylogenetic tree construction for confirmation is considered the gold standard. The genomic regions commonly used in this approach include core, E1, NS5 and 5 0 NC. 30 More recently, HCV genotyping has been determined indirectly by testing for type-specific antibodies with a competitive enzyme immunoassay. 31 However, although comparative analysis has shown a good overall agreement between serotyping and molecular genetic analysis 32 the sensitivity of PCR-based assays over serologic assays has been distinctly higher. 31, 32 Epidemiology of HCV genotypes Worldwide The worldwide distribution of HCV genotypes and their subtypes is shown in Table 1 . Genotypes 1, 2, and 3 are the most frequently encountered genotypes worldwide. [33] [34] [35] However, significant differences are noticed when subtype distribution is investigated. In North America and Northern Europe, 1a is the most common subtype followed by 2b and 3a. 36, 37 The most common subtype in Southern and Eastern Europe is 1b, followed by genotypes 2 and 3. 38, 39 Although HCV subtypes 2a and 2b are relatively common in North America and Europe, subtype 2c is found commonly in Northern Italy. 40 Subtype 3a, which is endemic in South East Asia, 34 has been encountered in Europe and the USA, and with relatively high frequency in intravenous drug abusers (IVDA). 41, 42 This leads to the suggestion that this subtype may have originated from South East Asia and was introduced to Europe and North America by travelers. 43 In North Africa, similar to the situation in Eastern and Southern Europe, HCV subtype 1b seems to predominate. [44] [45] [46] In Tunisia, subtype 1b is largely the dominant subtype (79%) followed by 1a, 2a, 2b, 3a, and 4. 43 In Morocco in contrast to Tunisia 45,46 subtype 1b, although the most prevalent, had lower prevalences (47-48%) but a higher circulation of genotype 2 (29-37%). 46 The pattern in Tunisia is reminiscent of that in Japan where subtype 1b accounts for 73% followed by genotype 2 (20%) and subtype 1a (2%). 34 Genotypes other than 1, 2 and 3 are actually more common among HCV-infected people in other parts of the world. Genotype 4 seems to be confined to the Middle East 47 and Central Africa, [48] [49] [50] while HCV genotype 5 has been isolated almost exclusively in South Africa 51 where it predominates, followed by genotypes 1, 2, 3, and 4, respectively. 51 Genotype 6 has been isolated in Hong Kong, Vietnam and throughout South East Asia. [52] [53] [54] In one study from Vietnam, genotype 1 was the most common genotype followed by genotypes 6-9 and genotype 2. 55 HCV genotypes 7, 8, and 9 have been identified mainly in Vietnamese patients, 56 while genotypes 10 and 11 have been reported from Indonesia. 57 It has been suggested that genotypes 7-11 are variants of the same group and should be classified as members of genotype 6. 16 It is interesting to note that in the Philippines, HCV subtype distribution is similar to that seen in North America and Northern Europe, where subtype 1a is the most common followed by 1b, 2a and 2b. 58 
Distribution of hepatitis C virus genotypes in the Middle East

Middle East
Distribution of HCV genotypes and subtypes in the Middle East 59-76 is shown in Table 2 . Surprisingly, the accumulated data show that there are two main patterns for the distribution of HCV genotypes: one is peculiar to the Arab countries (except for Jordan) where genotype 4 predominates, while the other pattern is characteristic of the non-Arab countries (Turkey, Israel, and Iran) where genotype 1 predominates. Although varying prevalences of genotype 4 have been reported from the Arab countries, it is noteworthy that genotype 4 is quasi-exclusive (91%) in Egypt which is also a North African country. [59] [60] [61] Based on only one known study in Jordan, 1a is the dominant subtype (40%) followed by 1b (33.3%) and genotype 4 (26.6%). 63 In Turkey 75, 76 and in Israel 62,74 subtype 1b is the dominant subtype (>70%) followed by 1a, similar to the pattern seen in Eastern and Southern Europe. 38, 39 Subtype 1a is the most common subtype in Iran followed by 3a, 1b, and 4. 72, 73 The two different patterns for the distribution of HCV genotypes in the Middle East are evident in the study conducted to determine genotypes of HCV in the Gaza Strip and Southern Israel. 62 The Gaza Strip borders the southern part of Israel and Egypt, and a few thousand inhabitants cross the border daily from Gaza to both countries. The most common genotypes found were type 1b (62%) in Southern Israel and type 4 (78%) in the Gaza Strip, corresponding to the most prevalent genotype in Egypt. 61 The high similarity between type 4 isolates from Gaza Strip and Egypt was demonstrated by sequence analysis of the HCV 5 0 NC region. 62 Subtype 1b in Israel was followed by subtypes 1a, 2a/2c, and 3a, respectively, and no genotype 4 was found. 62 Although genotype 4 is generally uncommon in Western countries, varying prevalences have been reported in Southern Europe. [77] [78] [79] During the past two years it has become evident that the number of patients infected with HCV genotype 4 in Europe 80,81 and the USA, 82 and most recently in Southern India, 83 is rising. This emerging pattern might reflect changing immigration patterns in those areas.
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Clinical significance of HCV genotypes
The significance of HCV genotyping as an epidemiological marker has been clearly substantiated, particularly in tracing the sources of infection and elucidating the possible modes of transmission. 84, 85 However, the issue of pathogenicity of the different genotypes/subtypes is still controversial. [9] [10] [11] 16 Several environmental, genetic, and immunological factors may contribute to the profound differences in disease progression observed in HCV infected patients. Therefore, longterm prospective studies in various population groups are still needed to generate reliable data on the clinical significance of HCV genotypes.
Antiviral therapy
In addition to the importance of HCV genotyping as epidemiological markers, most investigators agree on the significance of HCV genotypes as independent predictors of response to antiviral therapy. Major clinical trials of antiviral therapy for chronic HCV have been performed in Western countries 84, 85 and in Japan. 86 Hence, existing published data largely deal with patients with HCV genotypes 1, 2, and 3, and there are now clear-cut guidelines for the type of treatment and duration of antiviral therapy in such patients. 87 However there have been relatively few studies that have targeted patients infected with HCV genotype 4, and combination therapy clinical trials (interferon and ribavirin) for these patients have not been promising. [88] [89] [90] Encouraging results are now being reported on the efficacy of peginterferon in combination with ribavirin given for 48 weeks for the treatment of chronic hepatitis caused by HCV genotype 4 [91] [92] [93] [94] [95] [96] [97] with a sustained virologic response ranging from 63 to 82%. [91] [92] [93] [94] It is evident that more randomized controlled trials of the combined peginterferon plus ribavirin are needed to assess the optimal dosage and duration of therapy and for the eventual establishment of appropriate treatment protocols for these patients.
Challenges
It is now clear that HCV genotype 4 is the predominant genotype in the Middle East where one-fifth of the estimated 170 million HCV carriers live. In addition to the possible development of the infection into cirrhosis and HCC, it has been recently observed that there is an increased risk of liverrelated death and demand for liver transplantation in patients infected with HCV genotype 4. 98 These facts indicate that the treatment of carriers and prevention of HCV infection are very urgent problems. Efforts to develop more effective antiviral therapies and the establishment of an effective HCV vaccine remain the largest challenges for the near future.
